Back to top
more

NovoCure Limited (NVCR)

(Delayed Data from NSDQ)

$22.15 USD

22.15
1,045,650

-0.98 (-4.24%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $22.17 +0.02 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

NovoCure Limited [NVCR]

Reports for Purchase

Showing records 181 - 200 ( 211 total )

Company: NovoCure Limited

Industry: Medical Services

Record: 181

01/11/2017

Company Report

Pages: 4

Preannounces Record Number of Active Patients; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 182

01/06/2017

Daily Note

Pages: 17

ACA Uncertainty Creates Buying Opportunity; Previewing 5 Companies Expected to Preannounce Next Week

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 183

12/16/2016

Daily Note

Pages: 4

Key Opinion Leader Shares Perspectives on Optune''s Role in Treating GBM; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 184

12/15/2016

Industry Report

Pages: 31

Best Ideas List for 2017

Provider: WEDBUSH SECURITIES INC.

Analyst: LURIA G

Price: 75.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 185

12/13/2016

Daily Note

Pages: 6

Investor Day Highlights include New Data in Pancreatic and Ovarian Cancer

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 186

12/09/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 12

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 187

11/18/2016

Daily Note

Pages: 5

Update Reinforces Benefit of TTFields Therapy, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 188

11/02/2016

Company Report

Pages: 8

3Q Update, Optune Returns to Growth, Recent and Near- Term Catalysts should Drive Sales in Coming Quarters, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 189

10/17/2016

Daily Note

Pages: 39

3Q16 Preview: Stable Growth Trends Through The End of 2016

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 190

08/17/2016

Industry Report

Pages: 17

Medical Devices - Day 1: Key Takeaways from the PacGrow Healthcare Conference

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 191

07/29/2016

Company Report

Pages: 8

NVCR 2Q16: Scripts Come in Light but Key Elements in Place for Strong Growth, Reaffirming OUTPERFORM Rating but Reducing PT to $20

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 192

07/26/2016

Daily Note

Pages: 6

NCCN Guidelines Include Optune (TTFields) for Newly-Diagnosed GBM with a Favorable Category 2A Recommendation; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 193

07/22/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 25

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 194

07/15/2016

Daily Note

Pages: 41

Medical Devices: 2Q16 MedTech Preview: Stable Trends and Healthy Underlying Fundamentals

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 195

07/15/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 196

07/14/2016

Daily Note

Pages: 5

Smaller, Lighter, and Quieter is Good for the Patient and Potentially Outcomes; 2nd Gen Optune System Receives FDA Approval

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 197

07/05/2016

Daily Note

Pages: 7

Positive Management Meetings Help Address Investor Misunderstandings and Concerns; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 198

07/05/2016

Daily Note

Pages: 7

Positive Management Meetings Help Address Investor Misunderstandings and Concerns; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 199

05/19/2016

Industry Report

Pages: 8

ASCO 2016 Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 200

05/10/2016

Company Report

Pages: 8

New Prescriptions and Number of Active Users Exceed Expectations Underscoring Solid Adoption of Optune;Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party